上海医药
上海醫藥
상해의약
Shanghai Medical & Pharmaceutical Journal
2015年
20期
29-30,52
,共3页
慢性阻塞性肺疾病%D-二聚体三级预防
慢性阻塞性肺疾病%D-二聚體三級預防
만성조새성폐질병%D-이취체삼급예방
chronic obstructive pulmonary disease%D-dimer%tertiary prevention
目的:分析慢性阻塞性肺疾病(COPD)稳定期及急性加重期(AECOPD)患者血浆D-二聚体水平,探讨其在COPD三级预防中的应用.方法:收集2012年6月-2014年6月中心收治的COPD稳定期患者50例和急性加重期患者52例,检测血浆D-二聚体水平,并与50名正常者(对照组)进行比较.结果:急性加重期组的D-二聚体水平为1.02 mg/L,明显高于稳定期组的0.57 mg/L(P<0.05)和对照组的0.42 mg/L(P<0.001).结论:COPD稳定期及急性加重期患者血浆D-二聚体水平均高于正常人群,更易出现高凝状态,D-二聚体检测对COPD患者的三级预防有指导意义.
目的:分析慢性阻塞性肺疾病(COPD)穩定期及急性加重期(AECOPD)患者血漿D-二聚體水平,探討其在COPD三級預防中的應用.方法:收集2012年6月-2014年6月中心收治的COPD穩定期患者50例和急性加重期患者52例,檢測血漿D-二聚體水平,併與50名正常者(對照組)進行比較.結果:急性加重期組的D-二聚體水平為1.02 mg/L,明顯高于穩定期組的0.57 mg/L(P<0.05)和對照組的0.42 mg/L(P<0.001).結論:COPD穩定期及急性加重期患者血漿D-二聚體水平均高于正常人群,更易齣現高凝狀態,D-二聚體檢測對COPD患者的三級預防有指導意義.
목적:분석만성조새성폐질병(COPD)은정기급급성가중기(AECOPD)환자혈장D-이취체수평,탐토기재COPD삼급예방중적응용.방법:수집2012년6월-2014년6월중심수치적COPD은정기환자50례화급성가중기환자52례,검측혈장D-이취체수평,병여50명정상자(대조조)진행비교.결과:급성가중기조적D-이취체수평위1.02 mg/L,명현고우은정기조적0.57 mg/L(P<0.05)화대조조적0.42 mg/L(P<0.001).결론:COPD은정기급급성가중기환자혈장D-이취체수평균고우정상인군,경역출현고응상태,D-이취체검측대COPD환자적삼급예방유지도의의.
Objective: To analyze the plasma D-dimer level in the patients with chronic obstructive pulmonary disease (COPD) in the stable phase and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) to explore its application in the tertiary prevention.Methods:FromJune 2012 to June 2014,50 patients with COPD in the stable phase and 52 ones with AECOPD treated in the center were collected and the level of D-dimer was detected, which was compared with that in 50 healthy people (in the control group).Results:The level of D-dimer in the AECOPD patents was 1.02 mg/L which was signiifcantly higher than 0.57 mg/L in the group of COPD in the stable phase (P<0.05) and 0.42 mg/L in the control group (P<0.05).Conclusion:The levels of D-dimer in the patients with COPD in the stable phase and AECOPD were higher than that in the normal population, which is easier to appear hypercoagulability. The detection of D-dimer has the guiding signiifcance for the tertiary prevention in the COPD patients.